Skip to main content
OpenTrials
Completed

NCT Number: NCT05833646

Comparison of the Effects of ShotBlocker, Virtual Reality Glasses and Cold Application in Subcutaneous Heparin Injection

This study aims to compare the effects of ShotBlocker, virtual reality glasses and cold application on pain and patient satisfaction in patients who were applied subcutaneous low molecular weight heparin (LMWH) injection in adult patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ankara Yildirim Beyazit University Faculty of Health Sciences, Department of Nursing

Ankara, Çubuk, 06010, Turkey (Türkiye)

About this study

The research being carried out in Ankara City Hospital Clinic of Orthopedics. The research sample is expected to consist of 150 adult patients, who will be randomly divided into three groups. First group will be applied ShotBlocker (n=50); second group will be applied Virtual Reality Glasses (n=50) and third group will be applied subcutaneous LMWH via cold application (n=50). So as to assess the effect of the injection, it will be applied on patients' left side within abdomen site via standard method (control) while the same will be done on patients' right side according to method of intervention (intervention). Therefore, each patient will form both intervention and control groups. Prior to subcutaneous LMWH injection, "Descriptive Characteristics Form", which includes participants' socio-demographic attributes (gender, marital status, age, level of education, etc.), will be filled out by the researcher by means of face-to-face interview. Following the injection, in order to evaluate patients' pain, "Visual Analog Scale for Pain" will be filled while "Visual Analog Scale for Satisfaction" will be used in order to identify patients' satisfaction with the application. It is expected that compared to standard injection, ShotBlocker, virtual reality glasses and cold application will reveal more positive results on pain and patient satisfaction during subcutaneous LMWH injection in adult patients. Besides, the method that has the more effect will be determined by comparing different methods. It is thought the data collected by the research will contribute to literature.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Open to communication
  • 18 or over years of age
  • Received 1x0,4 ml enoksaparin sodium treatment
  • Experienced no complications during or after operation
  • Normal values of thrombocyte (150.000-300.000), aPTT (25-35 sec) and INR (0.8-1.2) (Thrombocyte, INR and aPTT tests will be assessed in accordance with reference values of the kits that the hospital uses.)
  • No infection, scar tissue or incision in abdomen site
  • Received no parenteral treatment other than this site
  • Not diagnosed with any sort of coagulation disorder
  • No visual impairment to be able to wear VR glasses
  • No allergy to cold
  • No mental or neurological disability
  • No audio-visual impairment disability to be able to watch the video
  • Turkish speaking and comprehending
  • Non-pregnant
  • No hematological or allergic disease
  • Willing to be hospitalized for 2 days
  • Volunteer to participate in the research will constitute the research sample.

Exclusion criteria

During data collection, those who;

  • Renounce from participating in the research
  • Remove virtual reality glasses during or after operation
  • Fail to hold the cold pack for necessary period of time
  • Show signs of cold allergy during operation
  • Change institutions or were discharged early during research
  • Change dose of drugs within drug system
  • Develop drawbacks in the abdomen site will be excluded from the research.

Treatment and study plan

Group 1

Device

In each group, patients will be applied both standard subcutaneous heparin injection and with ShotBlocker.

Other names: ShotBlocker

Group 2

Device

In each group, patients will be applied both standard subcutaneous heparin injection and with virtual reality glasses.

Other names: Virtual Reality Glasses (VRG)

Group 3

Device

In each group, patients will be applied both standard subcutaneous heparin injection and with cold application.

Other names: Cold Application

Primary outcomes

  1. Pain assessed by the VAS (Visual Analog Scale)

    Time frame: 4 month

    In this research, in order to assess patients' level of injection pain, Visual Analog Scale (VAS) will be used. It is a 10 cm scale, on each side of which there is "no pain" and "worst pain". In using VAS, the patient is informed that they are free to choose a spot between two endpoints and the destination from the start of "no pain" and the spot the patient chooses is measured and recorded as cm./ mm. In this assessment, mean pain scores ranging among 1-10 are given. Thus, while "0" refers to no pain, 1-4 VAS values refer to dull pain; 5-6 to moderate pain; 7-10 refer to worst pain. Results will be compared both within group and among all groups at the end of the research.

  2. Satisfaction assessed by the VAS (Visual Analog Scale)

    Time frame: 4 month

    VAS is also used to measure components other than pain. VAS-Patient Satisfaction is a 10 cm scale, on each side of which there is "Dissatisfied" and "Very Satisfied". After injection, the patient is expect to detect their level of satisfaction by synthesizing affecting factors related to the process and mark the level of satisfaction on a line with a cross (X). High scores obtained from the scale refer to high levels of patient satisfaction. Results will be compared both within group and among all groups at the end of the research.

Sponsors and collaborators

Lead sponsor

Ankara Yildirim Beyazıt University

Other

Registry information

Official study title

Comparison of the Effects of ShotBlocker, Virtual Reality Glasses and Cold Application on Pain and Patient Satisfaction in Subcutaneous Heparin Injection Application in Adult Patients

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Apr 27, 2023
Registry last updated
Feb 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.